Reuth Medical Center
Tel Aviv, Israel
NCT Number: NCT01237860
The study is designed to evaluate the safety and efficacy of using the L300 Plus as a neuroprosthesis device for walking in patients following an UMN injury or disease. The clinical study is proposed to determine the anticipated adverse event rate and treatment outcomes at the conclusion of the study.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 3
Tel Aviv, Israel
This is a prospective, one-center, single group, repeated measures, non inferiority study. Forty-five (45) subjects suffering from foot drop and thigh muscles weakness due to upper motor neuron injury or disease will be evaluated for this study. Each subject will be in the study for six weeks. Clinical benefits will be measured through an assessment of the gait performance. In particular it will test the hypothesis that the NESS L300 Plus System which involves foot drop correction with thigh muscles activation, may achieve walking enhancements not inferior to those gained from using a system that only corrects foot drop (i.e. NESS L300).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The patients will receive the device for daily use of six (6) weeks.
Other names: NESS L300, L300, L300 Plus
Time frame: Throughout the 6 weeks of the study
The occurence of anticipated and unanticipated events will be documented at each scheduled evaluation. In addition, subjects will be instructed to report adverse events 24 hours per day during the study period.
Time frame: Week 6
Patient feedback regarding the safety of using the device as reported during the study sessions and the completion of a satisfaction questionnaire will also be used to assess the system's safety.
Time frame: Week 1 and Week 6
This outcome measure includes the following: gait velocity, gait asymmetry, single limb support (percentage of the singe stance phase).
Time frame: Week 1 and Week 6
To imitate daily life situations, average gait speed will be also determine by measuring the time to walk 10m over an obstacle course, using the protocol in the Emory Functional Ambulation Profile.
Bioness Inc
Industry
Acronym: L300Plus
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06539247
Brain Diseases, Cardiovascular Diseases
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT05346640
Foot Drop, Mononeuropathies
San Francisco, California, United States
View Trial DetailsNCT05163782
Foot Drop, Mononeuropathies
Québec, Quebec, Canada
View Trial DetailsNCT05449275
Brain Diseases, Cardiovascular Diseases
Faisalabad, Punjab Province, Pakistan
View Trial Details